[go: up one dir, main page]

CO2018003500A2 - Anticuerpos anti-pd-1 y composiciones - Google Patents

Anticuerpos anti-pd-1 y composiciones

Info

Publication number
CO2018003500A2
CO2018003500A2 CONC2018/0003500A CO2018003500A CO2018003500A2 CO 2018003500 A2 CO2018003500 A2 CO 2018003500A2 CO 2018003500 A CO2018003500 A CO 2018003500A CO 2018003500 A2 CO2018003500 A2 CO 2018003500A2
Authority
CO
Colombia
Prior art keywords
antibodies
compositions
cancer
diseases
activity
Prior art date
Application number
CONC2018/0003500A
Other languages
English (en)
Inventor
Gunther Galler
Monika Gad
Klaus Koefoed
Ivan D Horak
Thomas Bouquin
Michael Kragh
Mikkel Pedersen
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57042898&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2018003500(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Symphogen As filed Critical Symphogen As
Publication of CO2018003500A2 publication Critical patent/CO2018003500A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención se refiere a anticuerpos anti-PD-1 y a métodos de uso de los mismos en el tratamiento de enfermedades y afecciones relacionadas con la actividad de PD-1, por ejemplo, cáncer.
CONC2018/0003500A 2015-10-02 2018-04-02 Anticuerpos anti-pd-1 y composiciones CO2018003500A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562236341P 2015-10-02 2015-10-02
PCT/EP2016/073421 WO2017055547A1 (en) 2015-10-02 2016-09-30 Anti-pd-1 antibodies and compositions

Publications (1)

Publication Number Publication Date
CO2018003500A2 true CO2018003500A2 (es) 2018-07-10

Family

ID=57042898

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0003500A CO2018003500A2 (es) 2015-10-02 2018-04-02 Anticuerpos anti-pd-1 y composiciones

Country Status (29)

Country Link
US (1) US11034765B2 (es)
EP (2) EP3368572B9 (es)
JP (1) JP6875385B2 (es)
KR (1) KR20180053752A (es)
CN (1) CN108290953B (es)
AU (1) AU2016333517B2 (es)
BR (1) BR112018006257A2 (es)
CA (1) CA3000564A1 (es)
CO (1) CO2018003500A2 (es)
CY (1) CY1125327T1 (es)
DK (1) DK3368572T3 (es)
ES (1) ES2924402T3 (es)
HR (1) HRP20221041T1 (es)
HU (1) HUE059788T2 (es)
IL (1) IL258214B2 (es)
LT (1) LT3368572T (es)
MX (1) MX2018003936A (es)
MY (1) MY190324A (es)
PE (1) PE20181044A1 (es)
PL (1) PL3368572T3 (es)
PT (1) PT3368572T (es)
RS (1) RS63490B1 (es)
RU (1) RU2750675C1 (es)
SA (1) SA518391262B1 (es)
SG (1) SG10201912943RA (es)
SI (1) SI3368572T1 (es)
TW (1) TWI751981B (es)
WO (1) WO2017055547A1 (es)
ZA (1) ZA201801852B (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240046641A (ko) 2015-04-17 2024-04-09 알파인 이뮨 사이언시즈, 인코포레이티드 조율가능한 친화성을 갖는 면역조절 단백질
US10513558B2 (en) 2015-07-13 2019-12-24 Cytomx Therapeutics, Inc. Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
PT3334763T (pt) 2015-08-11 2024-10-28 Wuxi Biologics Ireland Ltd Novos anticorpos anti-pd-1
CN107949573B (zh) 2015-09-01 2022-05-03 艾吉纳斯公司 抗-pd-1抗体及其使用方法
HK1251158A1 (zh) 2015-09-29 2019-01-25 细胞基因公司 Pd-1結合蛋白及其使用方法
US12030942B2 (en) 2015-10-02 2024-07-09 Les Laboratoires Servier Anti-PD-1 antibodies and compositions
EA201891093A1 (ru) 2015-11-03 2018-10-31 Янссен Байотек, Инк. Антитела, специфически связывающие pd-1, и их применение
IL310729A (en) 2016-04-15 2024-04-01 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
KR102536850B1 (ko) 2016-04-15 2023-05-26 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
JP7261379B2 (ja) 2016-06-20 2023-04-20 カイマブ・リミテッド 抗ｐｄ－ｌ１抗体
KR102257154B1 (ko) 2016-09-19 2021-05-28 셀진 코포레이션 Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
FI3515938T3 (fi) 2016-09-21 2025-03-27 Cstone Pharmaceuticals Monoklonaallisia vasta-aineita ohjelmoituun kuolemaan (PD-1)
RS62589B1 (sr) 2016-11-02 2021-12-31 Jounce Therapeutics Inc Antitela na pd-1 i njihova upotreba
TWI780083B (zh) 2016-11-18 2022-10-11 丹麥商賽門弗鎮公司 抗pd-1抗體及組成物
CA3046082A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Antibodies and methods of use thereof
CN110291109B (zh) 2017-01-20 2023-01-31 大有华夏生物医药集团有限公司 人程序性死亡受体pd-1的单克隆抗体及其片段
CA3054068A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
WO2018185232A1 (en) 2017-04-05 2018-10-11 Symphogen A/S Combination therapies targeting pd-1, tim-3, and lag-3
CN106939049B (zh) * 2017-04-20 2019-10-01 苏州思坦维生物技术股份有限公司 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用
EP3645740A4 (en) * 2017-06-25 2021-08-18 Systimmune, Inc. ANTI-PD-1 ANTIBODIES AND PROCESSES FOR PREPARATION AND USE
CN111356477B (zh) 2017-08-01 2024-08-30 Ab工作室有限公司 双特异性抗体及其用途
KR101917854B1 (ko) * 2017-08-24 2018-11-12 한국콜마주식회사 세포 수용체 결합능이 있는 펩티드를 포함하는 마이크로 캡슐 및 이를 포함하는 화장료 조성물
CN111712515A (zh) 2017-10-18 2020-09-25 高山免疫科学股份有限公司 变体icos配体免疫调节蛋白及相关组合物和方法
US12297253B2 (en) 2018-01-03 2025-05-13 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
TWI708787B (zh) 2018-03-02 2020-11-01 美商美國禮來大藥廠 Pd-1促效劑抗體及其用途
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
MA52289A (fr) 2018-04-18 2021-02-24 Xencor Inc Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
CA3099547A1 (en) 2018-05-07 2019-11-14 Reshma Abdulla RANGWALA Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
SG11202009986QA (en) 2018-05-07 2020-11-27 Genmab As Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
EP3823988A1 (en) * 2018-07-19 2021-05-26 Eli Lilly and Company Bispecific antibodies targeting immune checkpoints
JP7519985B2 (ja) * 2018-07-19 2024-07-22 タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド 抗ｐｄ－１抗体、投薬量、およびその使用
KR20210094509A (ko) * 2018-08-16 2021-07-29 무스크 파운데이션 포 리서치 디벨롭먼트 재조합 점액종 바이러스 및 이의 용도
AU2019338416A1 (en) * 2018-09-14 2021-04-29 Akso Biopharmaceutical, Inc. sPD-1 variant - Fc fusion proteins
US11377477B2 (en) * 2018-10-12 2022-07-05 Xencor, Inc. PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof
JP7475341B2 (ja) * 2018-10-31 2024-04-26 メルク・シャープ・アンド・ドーム・エルエルシー 抗ヒトｐｄ－１抗体結晶およびその使用方法
MX2021005394A (es) 2018-11-07 2021-07-06 Merck Sharp & Dohme Llc Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
CN111349162A (zh) * 2018-12-21 2020-06-30 神州细胞工程有限公司 人源化抗pd-1抗体及其用途
SG11202106347PA (en) * 2018-12-21 2021-07-29 Ose Immunotherapeutics Humanized anti-human-pd-1 antibody
AR118619A1 (es) * 2019-04-10 2021-10-20 Bio Thera Solutions Ltd Anticuerpos de unión a pd-1
KR20220030956A (ko) 2019-07-05 2022-03-11 오노 야꾸힝 고교 가부시키가이샤 Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
JPWO2021025140A1 (es) 2019-08-08 2021-02-11
PH12022550509A1 (en) 2019-09-06 2023-03-20 Servier Lab Anti-cd73 antibodies
US11851466B2 (en) * 2019-10-03 2023-12-26 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
CN112915202A (zh) * 2019-12-06 2021-06-08 正大天晴药业集团股份有限公司 喹啉衍生物与pd-1单抗的药物组合
CN113244385A (zh) * 2020-02-07 2021-08-13 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗恶性肿瘤中的用途
WO2021242663A1 (en) 2020-05-26 2021-12-02 Boehringer Ingelheim International Gmbh Anti-pd-1 antibodies
CA3191749A1 (en) * 2020-08-31 2022-03-03 Biosion Inc. Pd-1 binding antibodies and uses thereof
US20240024320A1 (en) 2020-11-17 2024-01-25 Seagen Inc. Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
AU2022217058A1 (en) * 2021-02-04 2023-09-21 Genuv Inc. Anti-pd-1 antibody and use thereof
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
KR20240046323A (ko) 2021-07-13 2024-04-08 비온테크 에스이 암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제
US20250066441A1 (en) 2021-07-19 2025-02-27 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
TW202322846A (zh) 2021-08-16 2023-06-16 美商再生元醫藥公司 新穎的il27受體促效劑及其使用方法
EP4413050A1 (en) 2021-10-04 2024-08-14 Les Laboratoires Servier Cancer therapy targeting nkg2a
WO2023057534A1 (en) 2021-10-06 2023-04-13 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
KR20250024872A (ko) 2022-05-11 2025-02-19 리제너론 파마슈티칼스 인코포레이티드 다중특이적 결합 분자 전구단백질 및 이의 용도
AU2023269545A1 (en) 2022-05-12 2024-11-14 BioNTech SE Binding agents capable of binding to cd27 in combination therapy
IL317207A (en) 2022-05-27 2025-01-01 Regeneron Pharma Interleukin-2 proproteins and their uses
AU2023278170A1 (en) 2022-06-04 2024-12-12 Regeneron Pharmaceuticals, Inc. Interleukin-2 proproteins and uses thereof
AU2023325400A1 (en) 2022-08-18 2025-02-27 Regeneron Pharmaceuticals, Inc. Interferon proproteins and uses thereof
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
CN120302979A (zh) 2022-12-01 2025-07-11 生物技术公司 针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗
US20240270836A1 (en) 2023-01-13 2024-08-15 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
AR131718A1 (es) 2023-01-30 2025-04-23 Kymab Ltd Anticuerpos
WO2024182540A2 (en) 2023-02-28 2024-09-06 Regeneron Pharmaceuticals, Inc. T cell activators and methods of use thereof
WO2024209072A1 (en) 2023-04-06 2024-10-10 Genmab A/S Multispecific binding agents against pd-l1 and cd137 for treating cancer
TW202448420A (zh) * 2023-04-28 2024-12-16 美商初始治療股份有限公司 用於減弱bhlh轉錄因子之myc原癌基因家族之c-myc或n-myc蛋白質的哺乳類轉譯之化合物、組合物及方法
WO2025106469A1 (en) 2023-11-14 2025-05-22 Regeneron Pharmaceuticals, Inc. Engineered heavy chain variable domains and uses thereof
WO2025114541A1 (en) 2023-11-30 2025-06-05 Genmab A/S Antibodies capable of binding to ox40 in combination therapy
WO2025122614A1 (en) 2023-12-05 2025-06-12 Regeneron Pharmaceuticals, Inc. Il18 receptor agonists and methods of use thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
TWI309240B (en) * 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
CN103059138B (zh) 2005-05-09 2015-10-28 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
CA2658474A1 (en) 2006-08-17 2008-02-21 F.Hoffmann-La Roche Ag A conjugate of an antibody against ccr5 and an antifusogenic peptide
PT2121920E (pt) 2007-03-01 2011-10-03 Symphogen As Método de clonagem de anticorpos cognatos
MX2011001930A (es) 2008-08-29 2011-04-21 Symphogen As Metodo para clonar anticuerpos derivados de aves.
JP2012501670A (ja) * 2008-09-12 2012-01-26 アイシス・イノベーション・リミテッド Ｐｄ−１特異抗体およびその使用
EP2342228B1 (en) * 2008-09-12 2017-09-06 Oxford University Innovation Limited Pd-1 specific antibodies and uses thereof
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CA2802344C (en) * 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
EP2691112B1 (en) 2011-03-31 2018-05-23 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
LT3081576T (lt) 2013-12-12 2019-10-25 Shanghai hengrui pharmaceutical co ltd Pd-1 antikūnas, antigeną surišantis jo fragmentas ir jų medicininis pritaikomumas
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2016106159A1 (en) 2014-12-22 2016-06-30 Enumeral Biomedical Holding, Inc. Anti-pd-1 antibodies

Also Published As

Publication number Publication date
HRP20221041T1 (hr) 2022-11-11
PE20181044A1 (es) 2018-07-03
RS63490B1 (sr) 2022-09-30
IL258214B2 (en) 2023-04-01
RU2750675C1 (ru) 2021-07-01
ES2924402T3 (es) 2022-10-06
EP4105235A1 (en) 2022-12-21
MX2018003936A (es) 2018-07-06
TWI751981B (zh) 2022-01-11
IL258214B (en) 2022-12-01
SI3368572T1 (sl) 2022-10-28
CN108290953B (zh) 2022-05-31
IL258214A (en) 2018-05-31
US20190144542A1 (en) 2019-05-16
CN108290953A (zh) 2018-07-17
CY1125327T1 (el) 2025-03-28
AU2016333517B2 (en) 2023-09-07
EP3368572B1 (en) 2022-05-25
KR20180053752A (ko) 2018-05-23
PL3368572T3 (pl) 2022-09-12
DK3368572T3 (da) 2022-08-08
WO2017055547A1 (en) 2017-04-06
AU2016333517A1 (en) 2018-04-12
BR112018006257A2 (pt) 2018-10-16
MY190324A (en) 2022-04-14
EP3368572A1 (en) 2018-09-05
HUE059788T2 (hu) 2022-12-28
SA518391262B1 (ar) 2021-07-28
LT3368572T (lt) 2022-07-25
SG10201912943RA (en) 2020-02-27
US11034765B2 (en) 2021-06-15
ZA201801852B (en) 2024-02-28
JP2018529359A (ja) 2018-10-11
PT3368572T (pt) 2022-06-23
EP3368572B9 (en) 2023-04-26
JP6875385B2 (ja) 2021-05-26
NZ740869A (en) 2024-12-20
TW201726734A (zh) 2017-08-01
CA3000564A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
CO2018003500A2 (es) Anticuerpos anti-pd-1 y composiciones
CO2019004003A2 (es) Composiciones y anticuerpos anti-lag-3
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
ECSP17034845A (es) Conjugados de anticuerpo- farmaco
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
CL2016001871A1 (es) Anticuerpos humanos para pd-1
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX391159B (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
MX2018000288A (es) Composiciones terapeuticas, combinaciones y metodos de uso.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO2022002622A2 (es) Anticuerpos anti-cd73 y composiciones
BR112017007170A2 (pt) anticorpos anti-ox40 humanizados e suas utilizações
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.
UY36480A (es) Uso de compuestos de picolinamida como fungicidas
MX388181B (es) Anticuerpos anti-pd-1.
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
MX2016010216A (es) Composiciones farmaceuticas solidas de antagonistas de los receptores de androgenos.
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
UY36499A (es) Uso de picolinamidas como fungicidas
MX389447B (es) Composiciones y métodos para anticuerpos dirigidos a bmp6.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX386860B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
DOP2016000312A (es) Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2